+++
1. DRUG ALLERGY (IGE-MEDIATED IMMEDIATE HYPERSENSITIVITY REACTIONS)
++
Prick skin testing for most low-molecular-weight drugs is not validated and is interpretable only if the test is positive at a nonirritating concentration. Testing for IgE-mediated allergy to penicillin (PCN) is validated; skin testing with the metabolic determinants of PCN has a high (more than 98%) negative predictive value. Referral of individuals with a listed PCN allergy to an allergist for evaluation is worthwhile because more than 90% have either lost sensitization or do not have a true PCN allergy. Such patients may then safely receive beta-lactam antibiotics, including penicillins and cephalosporins. Allergy testing to non-PCN drugs is more limited because it is either not standardized in practice or in reagent preparation, or the reaction may not be IgE-mediated; an allergist may provide guidance about the likelihood and severity of future exposures to determine whether re-challenging with the drug would be advisable.
+
Shenoy
ES
et al. Evaluation and management of penicillin allergy: a review. JAMA. 2019;321:188.
[PubMed: 30644987]
+++
2. NON-IGE–MEDIATED ANAPHYLACTIC DRUG REACTIONS
++
Non-IgE–mediated anaphylaxis induced by drugs resembles immediate hypersensitivity reactions but is not mediated by allergen-IgE cross-linking on mast cells or basophils. Mechanisms include direct mast cell activation (eg, opioids, vancomycin [vancomycin flushing syndrome], neuromuscular blocking agents, fluoroquinolones) via the Mas-related G protein coupled receptor-X2 receptors, complement activation–related pseudoallergy (possible mechanism for heparin or liposomal drug infusions [polyethylene glycol)/COVID mRNA vaccines], or IgG-mediated mechanisms. Contrary to IgE-mediated reactions, these reactions can often be prevented by prophylactic medical regimens. Some diseases that produce allergic or pseudoallergic conditions are listed in eTable 20–4.
++